How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors

Blood

Volumn 126, Issue 2, 2015, Pages 153-159

  Leissinger, Cindy A ^a   Singleton, Tammuella ^a   Kruse Jarres, Rebecca ^b  

^a TULANE UNIVERSITY MEDICAL CENTER   (United States)

^b Bloodworks   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ALLOANTIBODY; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; AUTOANTIBODY; BLOOD CLOTTING FACTOR 8; RECOMBINANT PROTEIN;

ANTIBODY TITER; ARTICLE; BLEEDING; BYPASSING AGENT PROPHYLAXIS; CASE REPORT; CHILD; HEMARTHROSIS; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; MALE; METRORRHAGIA; PHYSIOTHERAPY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; SEPSIS; SOFT TISSUE BLEEDING; SOFT TISSUE DISEASE; SUBSTITUTION THERAPY; ANTAGONISTS AND INHIBITORS; BLOOD; HEMORRHAGE; IMMUNOLOGY; QUALITY OF LIFE;

AUTOANTIBODIES; BLOOD COAGULATION FACTORS; CHILD; FACTOR VIII; HEMARTHROSIS; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE; QUALITY OF LIFE; RECOMBINANT PROTEINS;

EID: 84937786289     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-10-551952     Document Type: Article

References (75)

1. Brackmann HH, Wallny T. Immune tolerance: highdose regimen. In: Rodriguez-Merchan EC, Lee CA, eds. Inhibitors in Patients with Hemophilia. Oxford, United Kingdom: Blackwell Science; 2002:45-48.
2. Kasper CK. Diagnosis and management of inhibitors to factors VIII and IX. An introductory discussion for physicians. Treatment of Hemophilia Monograph Series, no. 34; September 2004.b Available at: http://www1.wfh.org/publication/files/ pdf-1178.pdf. Accessed August 29, 2014.
3. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;109(11):4648-4654.
4. Warrier I, Ewenstein BM, Koerper MA, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol. 1997;19(1):23-27.
5. Verbruggen B. Diagnosis and quantification of factor VIII inhibitors. Haemophilia. 2010;16(102): 20-24.
6. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol. 2004;77(2):187-193.
7. Ho AY, Height SE, Smith MP. Immune tolerance therapy for haemophilia. Drugs. 2000;60(3): 547-554.
8. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P; French FEIBA Study Group. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost. 1997;77(6):1113-1119.
9. White GC II, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J; Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560.
10. Pergantou H, Matsinos G, Papadopoulos A, Platokouki H, Aronis S. Comparative study of validity of clinical, X-ray and magnetic resonance imaging scores in evaluation and management of haemophilic arthropathy in children. Haemophilia. 2006;12(3):241-247.
11. Leissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia. 1999;5(suppl 3):25-32.
12. Scalone L, Mantovani LG, Mannucci PM, Gringeri A; COCIS Study Investigators. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia. 2006;12(2):154-162.
13. Turecek PL, Váradi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia. 2004; 10(suppl 2):3-9.
14. Hoffman M, Monroe DM III, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis. 1998;9(suppl 1):S61-S65.
15. Villar A, Aronis S, Morfini M, et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia. 2004; 10(4):352-359.
16. Váradi K, Negrier C, Berntorp E, et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost. 2003; 1(11):2374-2380.
17. Baxter Healthcare Corporation. FEIBA (antiinhibitor coagulant complex). Westlake Village, CA: Baxter Healthcare Corporation; November 2013.
18. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost. 2004;2(10):1700-1708.
19. Schneiderman J, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia. 2004;10(4):347-351.
20. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost. 1998;80(6):912-918.
21. Hilgartner MW, Knatterud GL. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood. 1983;61(1): 36-40.
22. Astermark J, Donfield SM, DiMichele DM, et al FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109(2):546-551.
23. Hay CR, DiMichele DM; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012; 119(6):1335-1344.
24. Mariani G, Kroner B. International immune tolerance registry, 1997 update. Vox Sang. 1999; 77(suppl 1):25-27.
25. DiMichele DM, Kroner BL; North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost. 2002;87(1):52-57.
26. Lenk H; ITT Study Group. The German Registry of immune tolerance treatment in hemophilia-1999 update. Haematologica. 2000; 85(10, suppl):45-47.
27. Haya S, López MF, Aznar JA, Batlle J; Spanish Immune Tolerance Group. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia. 2001;7(2): 154-159.
28. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al Treatment Guidelines Working Group on Behalf of The World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-e47.
29. National Hemophilia Foundation. MASAC [Medical and Scientific Advisory Council] Recommendation 179. MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Adopted November 4, 2007. Available at: http:// www.hemophilia.org/NHFWeb/MainPgs/ MainNHF.aspx?menuid557&contentid51007. Accessed August 29, 2014.
30. Aledort LM, Haschmeyer RH, Pettersson H; The Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med. 1994;236(4):391-399.
31. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544.
32. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost. 2011;9(4):700-710.
33. Valentino LA, Mamonov V, Hellmann A, et al Prophylaxis Study Group. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012;10(3): 359-367.
34. Manco-Johnson MJ, Kempton CL, Reding MT, et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost. 2013;11(6):1119-1127.
35. Windyga J, Lissitchkov T, Stasyshyn O, et al. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level, 1%) or moderately severe (FIX level #2%) haemophilia B. Haemophilia. 2014;20(1):15-24.
36. Valentino LA, Martinowitz U, Doolas A, Murali P. Surgical excision of a giant pelvic pseudotumour in a patient with haemophilia A. Haemophilia. 2006;12(5):541-544.
37. Antunes SV, Vicari P, Cavalheiro S, Bordin JO. Intracranial haemorrhage among a population of haemophilic patients in Brazil. Haemophilia. 2003; 9(5):573-577.
38. Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia. 2003;9(3):272-278.
39. Steen Carlsson K, Höjgård S, Glomstein A, et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia. 2003;9(5):555-566.
40. Shapiro AD, Donfield SM, Lynn HS, et al Academic Achievement in Children with Hemophilia Study Group. Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study. Pediatrics. 2001; 108(6):E105.
41. Penner JA, Kelly PE. Management of patients with factor vIII or IX inhibitors. Semin Thromb Hemost. 1975;1:386-399.
42. Kelly P, Penner JA. Antihemophilic factor inhibitors. Management with prothrombin complex concentrates. JAMA. 1976;236(18):2061-2064.
43. Yolken RH, Hilgartner MW. Prothrombin complex concentrates. Use in treatment of hemophiliacs with factor VIII inhibitors. Am J Dis Child. 1978; 132(3):291-293.
44. Buchanan GR, Kevy SV. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies. Pediatrics. 1978;62(5):767-774.
45. Schramm W. Experience with prophylaxis in Germany. Semin Hematol. 1993;30(3, suppl 2): 12-15.
46. Kreuz W, Escuriola-Ettingshausen C, Mentzer D. Factor VIII inhibitor bypass activity (FEIBA) for prophylaxis during immune tolerance induction (ITI) in patients with high-responding inhibitors [abstract]. Blood. 2000;96(suppl):266a. Abstract 1141.
47. Hilgartner MW, Makipernaa A, Dimichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia. 2003;9(3):261-268.
48. Dimichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia. 2006;12(4):352-362.
49. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia. 2007;13(3):249-255.
50. Morfini M, Auerswald G, Kobelt RA, et al. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia. 2007;13(5):502-507.
51. Jiménez-Yuste V, Alvarez MT, Martín-Salces M, et al. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations. Haemophilia. 2009; 15(1):203-209.
52. Valentino LA. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series. Haemophilia. 2009;15(3):733-742.
53. Ettingshausen CE, Kreuz W. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series. Haemophilia. 2010;16(1):90-100.
54. Young G, Auerswald G, Jimenez-Yuste V, et al. PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors. Thromb Res. 2012;130(6):864-870.
55. Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007;5(9):1904-1913.
56. Leissinger C, Gringeri A, Antmen B, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011; 365(18):1684-1692.
57. Antunes SV, Tangada S, Stasyshyn O, et al. Randomized comparison of prophylaxis and ondemand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia. 2014;20(1):65-72.
58. Hoots WK, Ebbesen LS, Konkle BA, et al Novoseven (F7HAEM-1505) Investigators. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia. 2008;14(3):466-475.
59. Gringeri A, Leissinger C, Cortesi PA, et al. Healthrelated quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study. Haemophilia. 2013;19(5):736-743.
60. Stasyshyn O, Antunes S, Mamonov V, et al. Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study. Haemophilia. 2014; 20(5):644-650.
61. Hay CRM. Inhibitors to factor VIII/IX: treatment of inhibitors-immune tolerance induction. In: Lee CA, Berntorp EE, Hoots WK, eds. Textbook of Hemophilia. Malden, MA: Blackwell; 2005:74-79.
62. Valentino LA. Secondary prophylaxis therapy: what are the benefits, limitations and unknowns? Haemophilia. 2004;10(2):147-157.
63. Tagliaferri A, Franchini M, Coppola A, et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia. 2008;14(5):945-951.
64. Gringeri A, Lambert T, Street A, Aledort L; Adolescent/Adult Prophylaxis Expert Working Group of the International Prophylaxis Study Group. Tertiary prophylaxis in adults: is there a rationale? Haemophilia. 2012;18(5):722-728.
65. Ewenstein BM, Valentino LA, Journeycake JM, et al. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia. 2004;10(5):629-648.
66. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia. 2004;10(2):134-146.
67. Morado M, Jimenez-Yuste V, Villar A, et al. Complications of central venous catheters in patients with haemophilia and inhibitors. Haemophilia. 2001;7(6):551-556.
68. Van Dijk K, Van Der Bom JG, Bax KN, Van Der Zee DC, Van Den Berg MH. Use of implantable venous access devices in children with severe hemophilia: benefits and burden. Haematologica. 2004;89(2):189-194.
69. Van Den Berg HM, Fischer K, Roosendaal G, Mauser-Bunschoten EP. The use of the Port-A-Cath in children with haemophilia-a review. Haemophilia. 1998;4(4):418-420.
70. Gringeri A, Leissinger C, Cortesi PA, et al. Healthrelated quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study. Haemophilia. 2013;19(5):736-743.
71. Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy-global progress towards optimal care. Haemophilia. 2006;12(1):75-81.
72. Soucie JM, Cianfrini C, Janco RL, et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood. 2004;103(7):2467-2473.
73. Leissinger C, Wulff K, Abdou A. Inhibitor prevalence and association with morbidity in severe hemophilia A patients. Blood. 2001;98(12): 535a.
74. Gringeri A, Mantovani LG, Scalone L, Mannucci PM; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood. 2003; 102(7):2358-2363.
75. Allen G, Aledort L. Therapeutic decision-making in inhibitor patients. Am J Hematol. 2006;81(1):71-72.